Tenaya Therapeutics, Inc. (TNYA)
NASDAQ: TNYA · Real-Time Price · USD
0.7300
+0.0040 (0.55%)
Jun 24, 2026, 10:20 AM EDT - Market open
Tenaya Therapeutics Employees
Tenaya Therapeutics had 70 employees as of December 31, 2025. The number of employees decreased by 27 or -27.84% compared to the previous year.
Employees
70
Change (1Y)
-27
Growth (1Y)
-27.84%
Revenue / Employee
$3,214
Profits / Employee
-$1,185,786
Market Cap
158.41M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 70 | -27 | -27.84% |
| Dec 31, 2024 | 97 | -43 | -30.71% |
| Dec 31, 2023 | 140 | -1 | -0.71% |
| Dec 31, 2022 | 141 | 35 | 33.02% |
| Sep 30, 2022 | 140 | 40 | 40.00% |
| Jun 30, 2022 | 135 | 50 | 58.82% |
| Mar 31, 2022 | 125 | 50 | 66.67% |
| Dec 31, 2021 | 106 | 31 | 41.33% |
| Sep 30, 2021 | 100 | 25 | 33.33% |
| Jun 30, 2021 | 85 | - | - |
| Mar 31, 2021 | 75 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ADC Therapeutics | 193 |
| Humacyte | 184 |
| Caribou Biosciences | 97 |
| OnKure Therapeutics | 45 |
| Corbus Pharmaceuticals Holdings | 36 |
| Enlivex | 34 |
| TuHURA Biosciences | 22 |
| Cognition Therapeutics | 14 |
TNYA News
- 19 days ago - Tenaya Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 19 days ago - Tenaya Therapeutics Slides: FY 2026 - Filings
- 20 days ago - Tenaya Therapeutics management to meet with Piper Sandler - TheFly
- 21 days ago - Tenaya Therapeutics Transcript: Study result - Transcripts
- 21 days ago - Tenaya Therapeutics Press release: Study result - Filings
- 21 days ago - Tenaya Therapeutics Slides: Study result - Filings
- 21 days ago - Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms - GlobeNewsWire
- 21 days ago - Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 - GlobeNewsWire